- Home
- SENEA vs CAPR Comparison
SENEA vs CAPR Comparison
Compare SENEA & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- CAPR
- Stock Information
- Founded
- SENEA 1949
- CAPR 2005
- Country
- SENEA United States
- CAPR United States
- Employees
- SENEA N/A
- CAPR N/A
- Industry
- SENEA Packaged Foods
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SENEA Consumer Staples
- CAPR Health Care
- Exchange
- SENEA Nasdaq
- CAPR Nasdaq
- Market Cap
- SENEA 573.0M
- CAPR 600.7M
- IPO Year
- SENEA N/A
- CAPR N/A
- Fundamental
- Price
- SENEA $88.50
- CAPR $6.34
- Analyst Decision
- SENEA
- CAPR Strong Buy
- Analyst Count
- SENEA 0
- CAPR 7
- Target Price
- SENEA N/A
- CAPR $39.29
- AVG Volume (30 Days)
- SENEA 21.3K
- CAPR 2.1M
- Earning Date
- SENEA 06-12-2025
- CAPR 05-13-2025
- Dividend Yield
- SENEA N/A
- CAPR N/A
- EPS Growth
- SENEA 25.61
- CAPR N/A
- EPS
- SENEA 5.45
- CAPR N/A
- Revenue
- SENEA $1,541,031,000.00
- CAPR $22,270,465.00
- Revenue This Year
- SENEA N/A
- CAPR $78.85
- Revenue Next Year
- SENEA N/A
- CAPR $157.99
- P/E Ratio
- SENEA $16.32
- CAPR N/A
- Revenue Growth
- SENEA 4.00
- CAPR N/A
- 52 Week Low
- SENEA $51.79
- CAPR $3.52
- 52 Week High
- SENEA $92.00
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- SENEA 54.01
- CAPR 27.28
- Support Level
- SENEA $84.66
- CAPR $12.16
- Resistance Level
- SENEA $91.68
- CAPR $13.22
- Average True Range (ATR)
- SENEA 2.51
- CAPR 1.22
- MACD
- SENEA 0.15
- CAPR -0.65
- Stochastic Oscillator
- SENEA 59.07
- CAPR 0.86
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.